Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Healey
    Healey
  2. Horwitz
    Horwitz
  3. McCormick
    McCormick
  4. Motzer
    Motzer
  5. Norton
    Norton
  6. Tap
    Tap

Groups

  1. Department of Medicine (4)
  2. Solid Tumor Oncology Division (3)
  3. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  4. Breast Medicine Service (1)
  5. Center for Hematologic Malignancies (1)
  6. Genitourinary Oncology Service (1)
  7. Hematologic Malignancies, Division of (1)
  8. Lymphoma (1)
  9. Orthopaedic Service (1)
  10. Population Sciences Research Program (1)
Search Within
  1. "Lancet"
  2. "2019"
Formats
  1. Journal Article (5)
Groups
  1. Department of Medicine (4)
  2. Solid Tumor Oncology Division (3)
  3. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  4. Breast Medicine Service (1)
  5. Center for Hematologic Malignancies (1)
  6. Genitourinary Oncology Service (1)

More Groups

People
  1. Beryl McCormick (1)
  2. John Healey (1)
  3. Larry Norton (1)
  4. Robert Motzer (1)
  5. Steven Horwitz (1)
  6. William Tap (1)
Years
  1. 2019 (5)
Publications
  1. Lancet (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: A randomised, phase 3, equivalence trial
    Journal Article

    Vicini, F. A.; Cecchini, R. S.; White, J. R.; Arthur, D. W.; Julian, T. B.; Rabinovitch, R. A.; Kuske, R. R.; Ganz, P. A.; Parda, D. S.; Scheier, M. F.; more...
    Lancet (2019)

    Fulltext@MSK | Save
  • Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): A randomised phase 3 trial
    Journal Article

    Tap, W. D.; Gelderblom, H.; Palmerini, E.; Desai, J.; Bauer, S.; Blay, J. Y.; Alcindor, T.; Ganjoo, K.; Martín-Broto, J.; Ryan, C. W.; more...
    Lancet (2019)

    Fulltext@MSK | Save
  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial
    Journal Article

    Rini, B. I.; Powles, T.; Atkins, M. B.; Escudier, B.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Lee, J. L.; more...
    Lancet (2019)

    Fulltext@MSK | Save
  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: A patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials
    Journal Article

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
    Lancet (2019)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial
    Journal Article

    Horwitz, S.; O'Connor, O. A.; Pro, B.; Illidge, T.; Fanale, M.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    Lancet (2019)

    Fulltext@MSK | Save